• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sustained Therapeutics advances novel drug delivery platform

January 6, 2023 By Sean Whooley

Sustained Therapeutics drug delivery platform
[Image courtesy of Sustained Therapeutics]
Sustained Therapeutics announced that it received regulatory approval in Canada to begin a Phase II trial of its novel pain medication.

Vancouver, BC-based Sustained Therapeutics develops a long-lasting non-opioid pain medication. Its trial evaluates a sustained-release platform technology to aid in chronic pain treatment.

The company said in a news release that it designed the medication to relieve both acute and chronic pain. It does so over longer periods with fewer side effects than the current standard of care, Standard Therapeutics said. The company’s Phase I trial resulted in a reduction in pain scores for three-quarters of participants. It found that effects lasted up to four weeks from a single dose, the company said.

Sustained Therapeutics received a no objection letter (NOL) from Health Canada to move forward with a five-center study. This study covers chronic pain as the company already has another Phase II trial underway for acute pain. Both trials use the sustained-release technology.

“The NOL from Health Canada is a clear indication that our clinical work is heading in the right direction,” said Dr. Martin Gleave, Sustained Therapeutics founder and CMO. “We’ve got a green light to start our next clinical trial and we expect patient enrollment to begin in the first quarter of 2023. This study will evaluate whether this treatment beats the current standard of care.”

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals, Regulatory/Compliance Tagged With: Sustained Therapeutics

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS